Naomi Pearce Archives | Page 4 of 15

Medicinal Cannabis in Australia | Part 2: Patient access via the Special Access Scheme (SAS) and Authorised Prescriber (AP) pathways

by Naomi Pearce | May 10, 2022 | Blog, Kate Legge, Naomi Pearce

Introduction As noted in part 1 of our blog series, the vast majority of medicinal cannabis products are not registered on the Australian Register of Therapeutic Goods (ARTG). Rather, they are unapproved therapeutic goods, i.e., products that have not been assessed...

Pearce IP leaders ranked by MIP in 2022

by Pearce IP | May 6, 2022 | Blog, Jacinta Flattery O’Brien PhD, Naomi Pearce, Our Awards

Pearce IP congratulates two of its patent leaders for being recognised by Managing IP (MIP) in its 2022 IP Stars ranking. Two Pearce IP leaders Naomi Pearce and Jacinta Flattery-O’Brien PhD are again ranked by MIP as Patent Stars. Naomi Pearce CEO, Executive...

Psychedelic Medicines Part 1

by Naomi Pearce | May 4, 2022 | Blog, Naomi Pearce

Depression, anxiety and related disorders are serious conditions whose treatment is – in many cases – not adequately addressed by existing psychiatric or psychological therapies. Despite the efforts of those seeking to develop novel treatments for these...

Medicinal Cannabis in Australia | Part 1: Available Products

by Naomi Pearce | May 4, 2022 | Blog, Naomi Pearce

Introduction Medicinal cannabis is now widely available in Australia. However, the vast majority of medicinal cannabis products are not registered on the Australian Register of Therapeutic Goods (ARTG). Rather, they are unapproved therapeutic goods, i.e., products...

Interlocutory Injunction To Restrain Further Threats Of Patent Infringement Proceedings Granted In Car Park Scrap

by Naomi Pearce | Apr 14, 2022 | Blog, Naomi Pearce

In the first such judgment since the 1980s, Justice Moshinsky has granted an interlocutory injunction to prevent TMA from threatening patent infringement proceedings against UbiPark’s customers pending judgment on the merits in the litigation. This case, UbiPark Pty...

Patent litigation in Australia just got a little cheaper

by Naomi Pearce | Apr 8, 2022 | Blog, Kate Legge, Naomi Pearce

The Full Court’s refusal of leave to appeal today in Novartis AG v Pharmacor Pty Limited [2022] FCAFC 58 is good news for the cost of patent litigation in Australia: it may have just become cheaper. The Full Court decision refusing Novartis’ application for leave to...